Posted by ABMN Staff on Apr 19th, 2024
Biogen (NASDAQ:BIIB – Get Free Report) had its price target reduced by equities research analysts at UBS Group from $250.00 to $214.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “neutral”...
More of this article »